Published in Arthritis Rheum on March 01, 2003
REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet (2009) 3.36
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther (2008) 2.15
CD40 and autoimmunity: the dark side of a great activator. Semin Immunol (2009) 1.80
T cells as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.75
Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol (2012) 1.74
Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest (2003) 1.63
Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov (2013) 1.53
Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.37
Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest (2005) 1.24
OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response. Immunity (2015) 1.17
Treating human autoimmunity: current practice and future prospects. Sci Transl Med (2012) 1.16
B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther (2003) 1.15
Why can't we find a new treatment for SLE? J Autoimmun (2009) 1.15
B cells in autoimmunity. Arthritis Res Ther (2009) 1.13
Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol (2011) 1.13
Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest (2006) 1.08
Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. Blood (2006) 1.08
The pathology of T cells in systemic lupus erythematosus. J Immunol Res (2014) 1.08
Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol (2009) 1.07
Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther (2011) 1.05
A novel monoclonal antibody to CD40 prolongs islet allograft survival. Am J Transplant (2012) 1.00
Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity (2010) 0.98
Immune and inflammatory role in renal disease. Compr Physiol (2013) 0.97
Abnormal costimulatory phenotype and function of dendritic cells before and after the onset of severe murine lupus. Arthritis Res Ther (2006) 0.95
T cells as a therapeutic target in SLE. Lupus (2015) 0.94
Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis. Arthritis Rheum (2010) 0.94
Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol (2013) 0.93
Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131). Protein Eng Des Sel (2013) 0.92
Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol (2004) 0.92
New and emerging treatment approaches to lupus. Biologics (2010) 0.92
New therapies for systemic lupus erythematosus. Clin Exp Immunol (2005) 0.92
Advances in drug therapy for systemic lupus erythematosus. BMC Med (2010) 0.92
The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin Exp Immunol (2011) 0.92
CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol (2006) 0.91
Biological therapy for lupus nephritis-tribulations and trials. Nat Rev Rheumatol (2010) 0.90
Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. Am J Transplant (2012) 0.90
Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism. ACS Chem Biol (2011) 0.90
Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol (2011) 0.89
Progress in Clinical Encapsulated Islet Xenotransplantation. Transplantation (2016) 0.88
Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Med (2013) 0.87
OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc Natl Acad Sci U S A (2014) 0.86
Aberrant CD40-induced NF-κB activation in human lupus B lymphocytes. PLoS One (2012) 0.86
Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res (2012) 0.86
Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol (2010) 0.85
Potential impact of B cells on T cell function in multiple sclerosis. Mult Scler Int (2011) 0.85
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity (2016) 0.84
Hurdles to the introduction of new therapies for immune-mediated kidney diseases. Nat Rev Nephrol (2016) 0.84
Hormonal milieu at time of B cell activation controls duration of autoantibody response. J Autoimmun (2014) 0.84
CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther (2015) 0.83
Biological therapies directed against cells in autoimmune disease. Springer Semin Immunopathol (2006) 0.83
Functional interaction of CD154 protein with α5β1 integrin is totally independent from its binding to αIIbβ3 integrin and CD40 molecules. J Biol Chem (2012) 0.83
Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus. Biomed Res Int (2014) 0.82
Costimulatory molecules as immunotherapeutic targets in systemic lupus erythematosus. Springer Semin Immunopathol (2006) 0.82
Blockade of CD40-TRAF2,3 or CD40-TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells. Immunology (2015) 0.82
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res Ther (2014) 0.81
Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment. Rheumatol Int (2009) 0.81
CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. Clin Dev Immunol (2011) 0.81
Costimulatory pathways: physiology and potential therapeutic manipulation in systemic lupus erythematosus. Clin Dev Immunol (2013) 0.81
Biological therapy in systemic lupus erythematosus. Int J Rheumatol (2012) 0.80
Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. Rheumatol Int (2005) 0.80
Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets. Best Pract Res Clin Rheumatol (2010) 0.79
The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol (2015) 0.79
Therapeutic CD154 antibody for lupus: promise for the future? J Clin Invest (2003) 0.79
Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights (2014) 0.79
Proinflammatory responses induced by CD40 in retinal endothelial and Müller cells are inhibited by blocking CD40-Traf2,3 or CD40-Traf6 signaling. Invest Ophthalmol Vis Sci (2014) 0.79
B-cell-dependent memory T cells impede nonmyeloablative mixed chimerism induction in presensitized mice. Am J Transplant (2011) 0.79
CD40 in coronary artery disease: a matter of macrophages? Basic Res Cardiol (2016) 0.78
Follicular helper T cell in immunity and autoimmunity. Braz J Med Biol Res (2016) 0.78
Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev (2017) 0.78
Novel treatments for systemic lupus erythematosus. Ther Adv Musculoskelet Dis (2011) 0.78
Update on CD40 and CD154 blockade in transplant models. Immunotherapy (2015) 0.78
Lupus nephritis: current issues. Ann Rheum Dis (2003) 0.78
Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol (2017) 0.77
Glucolipotoxicity initiates pancreatic β-cell death through TNFR5/CD40-mediated STAT1 and NF-κB activation. Cell Death Dis (2016) 0.77
Seeking approval: present and future therapies for pemphigus vulgaris. Curr Opin Investig Drugs (2008) 0.77
A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice. Diabetologia (2014) 0.76
Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis (2010) 0.76
Systemic lupus erythematosus: a therapeutic challenge for the XXI century. Clin Rheumatol (2014) 0.76
Imbalanced expression of functional surface molecules in regulatory and effector T cells in systemic lupus erythematosus. Braz J Med Biol Res (2014) 0.76
Increased expression of CD154 and FAS in SLE patients' lymphocytes. Rheumatol Int (2009) 0.76
Association of CD40 polymorphisms and haplotype with risk of systemic lupus erythematosus. Rheumatol Int (2015) 0.76
Increase in anti-Gal IgM level is associated with early graft failure in intraportal porcine islet xenotransplantation. Ann Lab Med (2015) 0.75
Current and Emerging Therapies for Lupus Nephritis. J Am Soc Nephrol (2016) 0.75
Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE). Pharmaceuticals (Basel) (2010) 0.75
Drugs, sun and T cells in lupus. Clin Exp Immunol (2004) 0.75
CD40-TRAF Signaling Upregulates CX3CL1 and TNF-α in Human Aortic Endothelial Cells but Not in Retinal Endothelial Cells. PLoS One (2015) 0.75
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Non-Human Primate Renal Allograft Rejection. Am J Transplant (2017) 0.75
Drugs in early clinical development for Systemic Lupus Erythematosus. Expert Opin Investig Drugs (2016) 0.75
Safe use of anti-CD154 monoclonal antibody in pig islet xenotransplantation in monkeys. Xenotransplantation (2017) 0.75
Expression, purification and biological characterization of the extracellular domain of CD40 from Pichia pastoris. BMC Biotechnol (2016) 0.75
Decrease of functional activated T and B cells and treatment of glomerulonephitis in lupus-prone mice using a natural flavonoid astilbin. PLoS One (2015) 0.75
CD40L and Its Receptors in Atherothrombosis-An Update. Front Cardiovasc Med (2017) 0.75
Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity. Clin Rev Allergy Immunol (2017) 0.75
New Insights on Platelets and Platelet-Derived Microparticles in Systemic Lupus Erythematosus. Curr Rheumatol Rep (2017) 0.75
[Novel B-cell directed strategies for the treatment of rheumatic diseases]. Z Rheumatol (2009) 0.75
Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med (2008) 9.61
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol (2004) 7.38
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med (2005) 6.83
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) (2012) 6.51
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum (2002) 4.98
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum (2012) 4.80
The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int (2004) 4.77
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet (2008) 4.33
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
Identification and characterization of circulating human transitional B cells. Blood (2005) 3.62
Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum (2005) 3.31
Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med (2010) 3.24
The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One (2012) 3.14
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med (2005) 2.92
Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum (2006) 2.90
Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med (2010) 2.62
Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum (2009) 2.58
Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) (2002) 2.51
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum (2005) 2.32
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum (2013) 2.06
Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion (2003) 2.05
Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol (2009) 2.03
Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med (2008) 1.97
RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med (2010) 1.94
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A (2010) 1.92
Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production. PLoS Genet (2011) 1.92
Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum (2006) 1.87
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum (2010) 1.86
Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney Int (2008) 1.86
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis (2012) 1.85
Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet (2008) 1.80
Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet (2013) 1.79
Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood (2013) 1.78
Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. JACC Cardiovasc Imaging (2011) 1.75
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol (2013) 1.72
Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum (2010) 1.67
Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum (2010) 1.65
Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus. J Rheumatol (2007) 1.63
Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest (2003) 1.63
MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol (2010) 1.59
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) (2013) 1.58
Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet (2011) 1.57
miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1. J Am Soc Nephrol (2013) 1.57
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum (2007) 1.53
Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol (2008) 1.51
Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum (2008) 1.50
Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum (2009) 1.48
Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun (2013) 1.47
Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum (2008) 1.41
Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction. Proc Natl Acad Sci U S A (2012) 1.38
Pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol (2009) 1.38
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis (2011) 1.37
MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndrome. Arthritis Rheum (2011) 1.31
Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjogren's syndrome. Autoimmunity (2009) 1.31
Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity (2012) 1.30
Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum (2004) 1.29
Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum (2008) 1.26
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum (2004) 1.25
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis (2007) 1.25
Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum (2006) 1.25
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood (2004) 1.23
The lupus family registry and repository. Rheumatology (Oxford) (2010) 1.21
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum (2012) 1.21
High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis (2011) 1.18
Biomarkers for systemic lupus erythematosus: a review and perspective. Curr Opin Rheumatol (2005) 1.17
Cytokines in Sjogren's syndrome: potential therapeutic targets. Ann Rheum Dis (2010) 1.15
Development of a gene transfer-based treatment for radiation-induced salivary hypofunction. Oral Oncol (2009) 1.15
Retraction of the suggestion to use the term "Reiter's syndrome" sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation. Arthritis Rheum (2007) 1.14
Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus. Proc Natl Acad Sci U S A (2007) 1.13
The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum (2002) 1.12
Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis (2012) 1.10
The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol (2002) 1.10
Transient detection of E1-containing adenovirus in saliva after the delivery of a first-generation adenoviral vector to human parotid gland. J Gene Med (2010) 1.09
Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J Rheumatol (2008) 1.07
Abnormal differentiation of memory T cells in systemic lupus erythematosus. Arthritis Rheum (2006) 1.06
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol (2008) 1.05
Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. Arthritis Rheum (2005) 1.05
Effects of a stress-reduction program on psychological function, pain, and physical function of systemic lupus erythematosus patients: a randomized controlled trial. Arthritis Rheum (2004) 1.03
Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis (2013) 1.03
Liver as a target for oligonucleotide therapeutics. J Hepatol (2013) 1.02
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis (2012) 1.02
A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol (2014) 1.02
Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol (2003) 1.02